Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies for cancer treatments, announced its upcoming participation in two major investor conferences. President and CEO Mark Velleca will present at the Stifel Healthcare Conference on November 19, 2024, at 4:10pm ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:00pm ET. Webcasts will be available on the company's website and archived for 90 days.
Black Diamond Therapeutics (Nasdaq: BDTX), un'azienda oncologica in fase clinica che sviluppa terapie MasterKey per il trattamento del cancro, ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori. Il presidente e CEO Mark Velleca presenterà alla Stifel Healthcare Conference il 19 novembre 2024, alle 16:10 ET, e alla Piper Sandler 36th Annual Healthcare Conference il 4 dicembre 2024, alle 15:00 ET. Saranno disponibili webcast sul sito web dell'azienda e saranno archiviati per 90 giorni.
Black Diamond Therapeutics (Nasdaq: BDTX), una empresa oncológica en fase clínica que desarrolla terapias MasterKey para tratamientos contra el cáncer, anunció su próxima participación en dos importantes conferencias para inversores. El presidente y CEO Mark Velleca presentará en la Stifel Healthcare Conference el 19 de noviembre de 2024, a las 4:10 p.m. ET, y en la Piper Sandler 36th Annual Healthcare Conference el 4 de diciembre de 2024, a las 3:00 p.m. ET. Las transmisiones web estarán disponibles en el sitio web de la empresa y se archivarán durante 90 días.
블랙 다이아몬드 테라퓨틱스 (Nasdaq: BDTX)는 암 치료를 위한 마스터키(MasterKey) 치료제를 개발하는 임상 단계의 온콜로지 기업으로, 두 개의 주요 투자자 컨퍼런스에 참여할 예정이라고 발표했습니다. 사장 겸 CEO 마크 벨레카는 2024년 11월 19일 오후 4시 10분 ET에 스티펠 헬스케어 컨퍼런스에서 발표하며, 2024년 12월 4일 오후 3시 ET에 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스에서도 발표할 예정입니다. 웹캐스트는 회사 웹사이트에서 제공되며 90일 동안 보관됩니다.
Black Diamond Therapeutics (Nasdaq: BDTX), une entreprise d'oncologie au stade clinique développant des thérapies MasterKey pour le traitement du cancer, a annoncé sa prochaine participation à deux grandes conférences pour investisseurs. Le président et directeur général Mark Velleca fera une présentation lors de la Stifel Healthcare Conference le 19 novembre 2024 à 16h10 ET, et lors de la Piper Sandler 36th Annual Healthcare Conference le 4 décembre 2024 à 15h00 ET. Des webdiffusions seront disponibles sur le site web de l'entreprise et archivées pendant 90 jours.
Black Diamond Therapeutics (Nasdaq: BDTX), ein klinisches Onkologieunternehmen, das MasterKey-Therapien für die Krebsbehandlung entwickelt, hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen angekündigt. Präsident und CEO Mark Velleca wird auf der Stifel Healthcare Conference am 19. November 2024 um 16:10 Uhr ET präsentieren und auf der Piper Sandler 36th Annual Healthcare Conference am 4. Dezember 2024 um 15:00 Uhr ET. Webcasts werden auf der Unternehmenswebsite verfügbar sein und 90 Tage lang archiviert werden.
- None.
- None.
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
- Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024
- Piper Sandler 36th Annual Healthcare Conference fireside chat at 3:00pm ET on Wednesday, December 4, 2024
Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
investors@bdtx.com
For Media:
media@bdtx.com
FAQ
When is Black Diamond Therapeutics (BDTX) presenting at the Stifel Healthcare Conference in 2024?
When is BDTX's presentation at the Piper Sandler Healthcare Conference in 2024?
How long will BDTX's investor conference webcasts be available for viewing?
Where can I watch Black Diamond Therapeutics (BDTX) investor conference presentations?
